Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention
Anne E. O’Shea, Franklin A. Valdera, Daniel C. Ensley, Todd R. Smolinsky, Jessica L. Cindass, Phillip M. Kemp Bohan, Annelies T. Hickerson, Elizabeth L. Carpenter, Patrick M. McCarthy, Alexandra M. Adams, Timothy J. Vreeland, Guy T. Clifton, George E. Peoples
Topics & Concepts
PI3K/AKT/mTOR pathwaySirolimusImmune systemCancer researchMechanistic target of rapamycinPharmacologyBiologyMalignancySignal transductionImmunologyCell biologyBiochemistryGeneticsPI3K/AKT/mTOR signaling in cancerPolyomavirus and related diseasesCancer Mechanisms and Therapy